MedTrace Logo

Prognostic Value of Androgen Receptor Expression and Mutations Within Oncogenes and Tumor Suppressor Genes in Patients Treated for High Risk Prostate Cancer With Proton Therapy (PRX32)

NCT03296124 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2018-11-16

No results posted yet for this study

Summary

Retrospective Review Study for Prognostic Transcriptional Output Related to Androgen Receptor Expression in Patients Treated for High Risk Prostate Cancer with Proton Therapy

Conditions

Sponsors & Collaborators

  • Driver

    collaborator UNKNOWN

  • University of Florida

    lead OTHER

Principal Investigators

  • Curtis M Bryant, MD, MPH · University of Florida Proton Therapy Institute

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-07
Primary Completion
2020-09-30
Completion
2020-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03296124 on ClinicalTrials.gov